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Association of functional polymorphisms in NOS1 and NOS3
with loudness dependence of auditory evoked potentials
Abstract
Nitric oxide (NO) is a gaseous molecule with neurotransmitter properties that is involved in numerous
functions in the central nervous system (CNS), the vascular system and also in macrophages.
Haplotypes of NOS1 and NOS3 genes have been shown to be associated with different psychiatric
disorders such as schizophrenia and bipolar disorder. Therefore, the detection of other characteristics of
nitrinergic transmission is desirable. Because nitrinergic functioning influences serotonergic
transmission, a functional marker of the serotonergic transmission, the loudness dependence of auditory
evoked potentials (LDAEP), can be assumed to be influenced by nitrinergic changes as well. In order to
clarify the relationship between nitrinergic transmission and LDAEP, 95 healthy subjects (41 males, 54
females) underwent electrophysiological recording and blood drawing for genotyping of single
nucleotide polymorphisms (SNPs) and haplotypes of the NOS1 and NOS3 genes. Interestingly, two
functional SNPs in both NOS1 (G-84A_exon 1c promoter polymorphism) and NOS3 (Glu298Asp) were
associated with lower LDAEP. Further studies are needed to fully clarify the relationship between
nitrinergic transmission, LDAEP and complex disorders such as schizophrenia and affective disorders.
Association of functional polymorphisms
in NOS1 and NOS3 with loudness dependence
of auditory evoked potentials
Wolfram Kawohl1*, Ina Giegling2*, Paraskevi Mavrogiorgou2, Oliver Pogarell2,
Christoph Mulert2, Hans-Ju¨rgen Mo¨ller2, Ulrich Hegerl4, Dan Rujescu2 and Georg Juckel3
1 Research Group Clinical and Experimental Psychopathology, Psychiatric University Hospital Zurich, Zurich, Switzerland
2 Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany
3 Department of Psychiatry, Ruhr-University Bochum, Bochum, Germany
4 Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany
Abstract
Nitric oxide (NO) is a gaseous molecule with neurotransmitter properties that is involved in numerous
functions in the central nervous system (CNS), the vascular system and also in macrophages. Haplotypes
of NOS1 and NOS3 genes have been shown to be associated with diﬀerent psychiatric disorders such as
schizophrenia and bipolar disorder. Therefore, the detection of other characteristics of nitrinergic trans-
mission is desirable. Because nitrinergic functioning inﬂuences serotonergic transmission, a functional
marker of the serotonergic transmission, the loudness dependence of auditory evoked potentials
(LDAEP), can be assumed to be inﬂuenced by nitrinergic changes as well. In order to clarify the
relationship between nitrinergic transmission and LDAEP, 95 healthy subjects (41 males, 54 females)
underwent electrophysiological recording and blood drawing for genotyping of single nucleotide
polymorphisms (SNPs) and haplotypes of the NOS1 and NOS3 genes. Interestingly, two functional
SNPs in both NOS1 (G-84A_exon 1c promoter polymorphism) and NOS3 (Glu298Asp) were associated
with lower LDAEP. Further studies are needed to fully clarify the relationship between nitrinergic
transmission, LDAEP and complex disorders such as schizophrenia and aﬀective disorders.
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Introduction
Nitric oxide (NO) is a gaseous molecule with neuro-
transmitter properties that is involved in numerous
functions in the central nervous system (CNS), the
vascular system and also in macrophages (Snyder and
Ferris, 2000 ; Yun et al., 1997). Unlike other neuro-
transmitters, NO is not stored in vesicles and thus
must be generated when release is required. A mani-
fold interaction between NO and serotonin has been
reported by diﬀerent animal studies : NO signalling
modulates serotonin release (Iuras et al., 2005 ;
Prast and Philippu, 2001; Segieth et al., 2001 ;
Smith and Whitton, 2000 ; Trabace and Kendrick,
2000), it enhances the post-synaptic serotonin response
(Straub et al., 2007), and aﬀects the reuptake of
serotonin (Bryan-Lluka et al., 2004 ; Kilic et al., 2003).
Additionally, interactions with serotonin reuptake
inhibitors (Harkin et al., 2003, 2004 ; Inan et al., 2004)
and modulations of 5-HT1 receptors (Chiavegatto and
Nelson, 2003 ; Pitsikas et al., 2005) have been reported.
Furthermore, a recent paper by Chanrion et al.
(2007) was able to show that the neuronal nitric oxide
synthase (nNOS) interacts with the C terminus of the
serotonin transporter (SERT) and that co-expression of
nNOS and SERT in HEK293 cells decreased SERT cell
surface localization and serotonin uptake.
NO dynamics are determined by nitric oxide
synthase (NOS) activity (Snyder and Ferris, 2000).
NOS catalyses the synthesis of NO from the amino
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acid L-arginine in an enzymatic reaction with nic-
otinamide adenine nucleotide phosphate (NADPH) as
a co-factor. Three isoforms of the enzyme have been
puriﬁed, nNOS or NOS-I, the neuronal form; iNOS or
NOS-II, the macrophage form; and eNOS or NOS-III,
the endothelial form. NOS-I and NOS-III are involved
in CNS neurotransmission.
NOS-I forms the main source on NO in excitable
tissues, it can be found in 1% of all neurons (Snyder
and Ferris, 2000). As revealed by immunohisto-
chemical and autoradiographic studies, the distribu-
tion of NOS-I achieves its maximum in the cerebellum
followed by the hippocampus and neocortex (Bredt
and Snyder, 1989 ; Kidd et al., 1995). Another enzyme
inﬂuencing NO function in the brain is the endothelial
nitric oxide synthase (NOS-III) (Reif et al., 2006b). Mice
lacking NOS-III show a low rate of neural stem cell
proliferation, and in an animal model of depression,
i.e. the learned helplessness paradigm, those mice
show a poorer responsiveness (Reif et al., 2004).
NOS-III is expressed in the endothelium of the CNS
and has been hypothesized to also be present in
neurons such as the CA1 pyramidal cells (Dinerman
et al., 1994 ; Doyle and Slater, 1997; O’Dell et al., 1994).
NOS1 and NOS3 haplotypes have been shown to be
associated with diﬀerent psychiatric disorders such as
schizophrenia, bipolar disorder (Reif et al., 2006a,b)
and suicidal behaviour (Rujescu et al., 2007) making
them candidate genes of considerable interest.
Due to its gaseous properties, N-functioning itself is
not easily detectable in vivo. Another marker of NO
functioning, i.e. NOS enzyme activity, is also not easily
determinable, especially in humans. Due to its close
interactions with the serotonergic system, a marker of
the serotonergic activity may provide more insight in
human nitrinergic neurotransmission. The loudness
dependence of auditory evoked potentials (LDAEP) is
widely used as a well established and reliable measure
of central serotonergic activity (Hegerl et al., 2001;
Hegerl and Juckel, 1993, 1994, 2000 ; Juckel et al., 1996).
LDAEP is the change in amplitude of auditory evoked
potentials in response to diﬀerent stimulus intensities.
The inverse relationship between LDAEP and central
serotonergic activity has been shown by diﬀerent
methods. LDAEP has been compared to direct sero-
tonin markers such as 5-hydroxyindolacetic acid
(5-HIAA) in the cerebrospinal ﬂuid in humans (von
Knorring and Perris, 1981) and in animal models
(Ehlers et al., 1991 ; Pineda et al., 1991). In awake
cats, microinjection of the 5-HT1A agonist 8-OH-DPAT
into the dorsal raphe nuclei inhibits the ﬁring rate of
serotonergic neurons via an autoreceptor feedback
loop. This has been shown to cause a higher loudness
dependence in recordings from the primary auditory
cortex (Juckel et al., 1999), an area underlying dense
serotonergic innervation with ﬁbres from the dorsal
raphe nuclei (Jacobs and Azmitia, 1992 ; Lewis et al.,
1986). LDAEP changes have also been found in
diﬀerent psychiatric disorders such as depression,
schizophrenia, obsessive–compulsive disorder and
alcohol dependency (Chen et al., 2005 ; Hegerl et al.,
1996 ; Juckel et al., 2003 ; Pogarell et al., 2004).
Thus, modiﬁcations in nitrinergic transmission may
be accompanied by altered LDAEP via nitrinergic–
serotonergic interaction.
An interrelation of nitrinergic transmission with
LDAEP as a marker of serotonergic transmission
might be detectable by genetic association. Subjects
carrying NOS1 and NOS3 variants inﬂuencing nitri-
nergic transmission may exhibit loudness dependence
diﬀerences compared to subjects without these speciﬁc
polymorphisms.
Materials and methods
Subjects
Unrelated healthy volunteers of German descent (i.e.
both parents German) were randomly selected from
the general population of Munich, Germany, and
contacted by mail. To exclude subjects with neuro-
psychiatric disorders or subjects who had ﬁrst-
degree relatives with neuropsychiatric disorders, we
conducted further screenings before the volunteers
were enrolled in the study. First, subjects who re-
sponded were initially screened by phone. Detailed
medical and psychiatric histories were assessed for
both themselves and their ﬁrst-degree relatives by
using systematic forms. Second, they were invited to a
comprehensive interview including the Structured
Clinical Interview for DSM-IV (SCID I and SCID II)
(First et al., 1997 ; Wittchen et al., 1997) to evaluate
their lifetime Axis I and II disorders. Psychiatric diag-
noses among their ﬁrst-degree relatives were also as-
sessed using the Family History Assessment Module
(Rice et al., 1995). Subjects with relevant somatic dis-
eases or hearing problems (objectiﬁed by standardized
1000 Hz tone audiometry) or a lifetime history of any
Axis I or II psychiatric disorders were excluded.
Subjects who had ﬁrst-degree relatives with a lifetime
history of a mental disorder were also excluded.
Finally, 95 healthy subjects (41 males, 54 females) were
included that underwent electrophysiological record-
ing and blood drawing for genotyping. Their mean
age was 43¡15 yr (range 19–72 yr). In total, 26.3% had
attained a low educational level, 25.3% a middle and
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48.4% a high educational level. The study was ap-
proved by the ethics committee of the Ludwig-
Maximilians-University of Munich. All subjects gave
written informed consent.
Genotyping
Genotyping of all 55 single nucleotide polymorphisms
(SNPs) was performed using the following methods.
Seven SNPs (NOS1 : rs2682826, rs1353939, rs693534,
rs2293049; NOS3: rs2070744, rs1799983, rs891512)
were genotyped by Illumina (Illumina Inc., San Diego,
CA, USA) using their Integrated BeadArray System.
We supplied Illumina with bar-coded DNA microtitre
plates containing the DNA quantiﬁed with Pico Green
to be at 100 ng/ml and Illumina delivered genotypes
with a quality score calculated by proprietary Illumina
algorithms. A further 17 SNPs were genotyped at the
Genetics Research Centre (GRC) using iPLEX assays
on the MassARRAY MALDI-TOF mass spectrometer
(Sequenom, Hamburg, Germany). SNPs were selected
from the NCBI SNP database (http://www.ncbi.nlm.
nih.gov) and ‘Tagger’ (http://www.broad.mit.edu/
mpg/tagger/server.html). Only validated SNPs with
a minor allele frequency of>1% were selected.
Additionally, 31 SNPs in genes spanning all
chromosomes were included as genomic controls
(CLCA1, EDARADD, MYO3B, XDH, HRG, UBE1C,
CORIN, GALNT7, BVES, ELOVL5, FGL2, ANXA13,
XPO7, SH3GL2, AKR1CL2, LHPP, RAB30, RAG1,
CD69, TEP1, ZFYVE21, OCA2, DC13, PELP1, CYB5,
RAB31, BRUNOL5, RPS5, RIN2, MRPL39, HDAC10)
and genotyped by Illumina. These genes were selected
based on the low a-priori probability of involvement
in behavioural traits and phenotypes.
Neurophysiological assessment
AEP recording (SynAmps Neuroscan1, El Paso, TX,
USA) was performed with the patients’ eyes open.
Tones (1000 Hz, 40 ms duration, ISI 1800–2200 ms)
of ﬁve intensities (60, 70, 80, 90, 100 dB SPL) were
presented binaurally over headphones. At least 40
artifact-free (¡50 mV) sweeps/intensity were averaged.
N1 peaks (60–125 ms) and P2 peaks (110–210 ms)
were determined semi-automatically at Cz electrodes
(linked mastoids reference). In order to reduce short-
term habituation eﬀects, the ﬁrst ﬁve responses to each
intensity were rejected. The remaining sweeps (at least
40 per intensity) were averaged separately for each
person and each intensity. N1 and P2 peaks were
determined at the Cz electrode. The N1/P2 amplitude
was deﬁned as the diﬀerence between N1 and P2.
The LDAEP was calculated as a linear regression slope
with stimulus intensity as independent and N1/P2
amplitude as dependent variables. (For more details
see Gallinat et al., 2000 ; Hegerl and Juckel, 1993.)
Statistics
Haploview 3.2 was used to generate a linkage dis-
equilibrium map and to test for Hardy–Weinberg
equilibrium (Barrett et al., 2005). Tests for associations
using the multi-marker haplotypes were performed
using the software environment ‘R’ (http://www.R-
project.org). Single haplotype signiﬁcance and odds
ratios were calculated as well as global signiﬁcance.
Permutation (10 000 permutations) was also used
to estimate the global signiﬁcance of the results for
haplotype analyses and to validate the EM values. For
comparison of loudness dependence values between
haplotypes the ‘R’ package ‘haplo.score’ was used
(Schaid et al., 2002). The following covariates were
included into analysis : sex (t=x2.290, d.f.=93,
p=0.024, with higher scores in females) and age (cor-
relation: r=x0.246, p=0.016). The suite of R routines,
referred to as ‘haplo.score’, can be used to compute
score statistics to test associations between haplotypes
and a wide variety of traits, including binary, ordinal
and quantitative traits. These methods assume that
all subjects are unrelated and that haplotypes are
ambiguous. The methods provide several diﬀerent
global and haplotype-speciﬁc tests for association, as
well as adjustment for non-genetic covariates and
computation of simulated p values (Schaid et al., 2002).
Single locus marker tests were also performed using
analysis of variance (ANOVA) for LDAEP values at Cz
controlled for the covariates sex, age and educational
level if appropriate using SPSS 15.0 software (SPSS
Inc., Chicago, IL, USA).
Results
As expected, none of the 31 SNPs in the genomic
control genes showed an association with loudness
dependence. One putative NOS1 SNP (rs2293049)
was excluded from statistical analysis because it
was not polymorphic in our sample. Two further
NOS1 SNPs were excluded due to their deviation
from the Hardy–Weinberg equilibrium (rs2682826,
rs1353939).
The remaining 18 SNPs in NOS1 (Figure 1) and all
SNPs in NOS3 were in Hardy–Weinberg equilibrium
(p>0.05). Figure 2 shows the linkage disequilibrium
(LD) within NOS1. LD patterns for NOS3 show a
weak to moderate LD (Dk=0.83) between two SNPs
(rs1799983 and rs891512).
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NOS1
Single marker analyses showed associations between
LDAEP and two SNPs: a potentially functional SNP
(G-84A_exon 1c promoter polymorphism; Reif et al.,
2006a; allele : F=7.539, d.f.=1, 152, p=0.007), with
T carriers showing lower LDAEP values, remaining
signiﬁcant after correction for multiple comparisons,
and rs693534 (genotype: F=3.030, d.f.=2, 91, p=
0.053 ; AA homozygotes vs. G allele carrier : F=5.260,
d.f.=1, 92, p=0.024) with the G allele carrier showing
lower LDAEP values. This could also be seen in a
haplotype analysis including both SNPs from block 4
(rs693534 and rs378221) (haplotype frequency=0.385,
haplotype score=x2.287, simulated p=0.020) with
GG carriers showing lower scores.
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Figure 1. Overview of the NOS1 gene region, intron/exon structure and single nucleotide polymorphism sites.
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Figure 2. Linkage disequilibrium (LD) of the 18 single nucleotide polymorphisms in NOS1. Regions of high LD (Dk=1 and
LOD>2) are shown in bright red ; decreasing colour intensity indicates decreasing Dk value. Regions with high Dk values (=1)
but low informativeness (LOD<2) are shown in light blue. Regions of low LD and low LOD scores (Dk<0.2, LOD<2) are shown
in white.
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NOS3
As the three remaining SNPs were either not in, or
in weak to moderate, LD we did not perform haplo-
type analysis for NOS3. Interestingly, the only signiﬁ-
cant association was seen with a functional SNP
(Glu298Asp; rs1799983; allele : F=4.510, d.f.=1, 185,
p=0.035) with the T (Asp) allele carrier showing lower
LDAEP values.
Discussion and conclusion
We detected associations of two functional poly-
morphisms in NOS1 and NOS3 with a lower LDAEP.
The ﬁndings support the hypothesis that the NO
system may have an inﬂuence on LDAEP. A plausible
explanation would be a modulation via serotonergic
functioning. A low LDAEP has been shown to be
an epiphenomenon of higher serotonergic activity
(Juckel et al., 1997). A subsequent change of LDAEP is
plausible and supported by our ﬁndings. The –84A_
exon 1c SNP was associated with a 30% decrease in
NOS1 exon 1c expression levels (Saur et al., 2004).
Additionally, this SNP impacted on prefrontal func-
tioning as assessed by neuropsychological testing and
electrophysiological parameters (Reif et al., 2006a).
The functional SNP in NOS3 which was associated
with a lower LDAEP is localized in exon 8 and leads
to an amino-acid exchange (Glu298Asp; rs1799983).
The consequences of diﬀerent SNPs on NOS activity
are unclear. In the case of lower LDAEP, lower
NO functioning may be assumed, while the complex
property of the serotonergic system and the incom-
pletely clariﬁed interaction on the cellular level must
be taken into account.
One limitation of our study is the still incompletely
clariﬁed and presumably indirect interrelation be-
tween the modulating function of serotonin concern-
ing LDAEP on one hand and properties of nitrinergic
transmission on the other. Whether serotonin is the
only neurotransmitter inﬂuencing LDAEP has been
discussed (Juckel et al., 1997 ; O’Neill et al., 2006),
dopamine seems to be a promising inﬂuencing
factor. Due to the inﬂuence of nitrinergic transmission
on dopaminergic transmission (Reif et al., 2006a),
at least an additional interaction : nitrinergic trans-
missionpdopaminergic transmissionp serotonergic
transmission is possible. Other limitations are the
relatively low sample size and the possibility that un-
known stratiﬁcation biases may have not been taken
into account. This is an association study, so causal
connections between polymorphisms and LDAEP
changes are unproven and can only be assumed.
In summary, LDAEP changes and also certain
NOS1 and NOS3 polymorphisms have both been
shown to be associated with psychiatric disorders
such as schizophrenia and aﬀective disorders (Reif
et al., 2006a, b) and, according to our ﬁndings, LDAEP
may be inﬂuenced by nitrinergic neurotransmission in
humans via serotonergic changes inﬂuenced by NO.
These novel ﬁndings warrant further replications
including larger subject numbers. Moreover, further
research including experimental changes in NO
activity should be fruitful in elucidating the inﬂuence
of nitrinergic transmission on LDAEP and on complex
disorders subsequently.
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